VANGUARD GROUP INC 13D and 13G filings for Seelos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-09 11:32 am Sale | 2022-12-30 | 13G | Seelos Therapeutics, Inc. SEEL | VANGUARD GROUP INC | 1,306 4.680% | -34 (-2.52%) | Filing |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | Seelos Therapeutics, Inc. SEEL | VANGUARD GROUP INC | 1,340 5.030% | 611 (+83.81%) | Filing |
| 2021-02-10 11:52 am Purchase | 2020-12-31 | 13G | Seelos Therapeutics, Inc. SEEL | VANGUARD GROUP INC | 729 5.240% | 729 (New Position) | Filing |